Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol’s Opdivo Is First Checkpoint Inhibitor Cleared For Blood Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA granted Opdivo an ultra-rapid approval for the treatment of classical Hodgkin lymphoma that has relapsed or progressed, making it the first PD-1 inhibitor approved for hematological cancer.

You may also be interested in...

Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved

The latest drug development news and highlights from our FDA Performance Tracker.

Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big

Novartis is closing its high-profile cell and gene therapy unit – the one responsible for developing CAR-T therapies. The move suggests Novartis’s outlook for the CAR-T field may be changing, though it’s not clear why.

One Down, Two To Go For Adcetris’ Expansion In Lymphoma

Takeda/Seattle Genetics announced positive Phase III data from the ALCANZA trial evaluating the antibody drug-conjugate in patients with cutaneous T-cell lymphoma (CTCL). Phase III studies in other potentially larger lymphoma indications are ongoing.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts